Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Sorin completes first implant of new generation CRT-D

Sorin : 01 May, 2008  (New Product)
Sorin Group Cardiac Rhythm Management has completed the first implant in a clinical trial of its new-generation Paradym 8770 sonR cardiac resynchronization therapy defibrillator (CRT-D).
The system contains a technology, named sonR, which is designed to adjust CRT delivery based on haemodynamic response as opposed to conventional CRT-D devices,that monitor the electrical activity of the heart. Paradym sonR is the first device delivering continuous management of resynchronization therapy during patients' everyday life.

Previous clinical studies have shown that up to 25 percent of patients, who meet the criteria for CRT and who are implanted with a CRT-D device do not benefit from the therapy. Studies suggest that, in order to improve therapy success rate, it is important to offer each patient a tailor-made programming of the timing between electrical impulses sent to different parts of the heart (CRT settings).

Manual programming of CRT settings can be guided using echocardiography, but echo optimisation is not applied for all patients because it is a time-consuming and non-standardised procedure. Moreover, patient status can change over time, due to many factors (modifications of drug regimen, life-style changes, and modification of heart dimension). It is therefore crucial to re-assess and re-adjust the CRT settings on a regular basis.

Fred Hrkac, president of Sorin Group Cardiac Rhythm Management (CRM) Business Unit commented: “The sonR sensor is one of our most promising innovations in the treatment of heart failure because it allows to automatically re-adjust the CRT settings. Whereas conventional devices look at the heart as a ‘clock’, new Paradym sonR looks at the heart as a ‘pump’, measuring vibrations generated by heart contraction. Thanks to this innovative approach, we provide the medical community and their patients with a completely new system, and this is in line with our vision to become an innovative leader in haemodynamic management of heart failure”.

The new Paradym device with its sonR functionality is designed to measure and evaluate the performance of the cardiac pump, and to adapt the CRT settings to the patients' cardiac status automatically and recurrently during patients' everyday life.

A multi-centre clinical trial including 150 patients is currently being conducted across Europe. The first sonR systems, the Paradym sonR CRT-D, including the sonR FIX atrial lead, were implanted by prof Angelo Auricchio from Cardiocentro Ticino in Lugano, Switzerland, Dr Peter Paul Delnoy from Isala Clinics in Zwolle, Netherlands, and Dr Neil Sulke from Eastbourne General Hospital in the United Kingdom.

Dr Peter Paul Delnoy declared: “Optimal resynchronization of the ventricles in heart failure patients is crucial for the success of the therapy. With the new sonR sensor, the device is designed to adjust CRT settings for each patient recurrently during daily life including both rest and exercise.”


The Paradym family also includes a single-chamber (VR 8250), and a dual-chamber (DR 8550) implantable cardioverter defibrillator for the management of arrhythmias.

“I'm excited about the comprehensive range of therapeutic tools that Paradym DR offers. I like the small profile and the high energy output (42J) which provides extra safety margin for patients with high defibrillation thresholds. That, coupled with SafeR to reduce unnecessary ventricular pacing and Parad+ to reduce inappropriate shocks, makes this an ideal ICD for my patients”, said Dr Franck Krumel from the Herz-und Gefasszentrum Bad Bevensen, Germany, primary investigator of the Paradym Clinical Release study, who implanted the first Paradym DR.

According to the European Society of Cardiology (ESC) and the American Heart Association (AHA), more than 10 million Europeans and five million Americans suffer from heart failure, the most costly cardiovascular disease.
Cardiac resynchronization therapy defibrillators are indicated in advanced heart failure patients who might be at risk for Sudden Cardiac Death (SCD).

CRT-D devices are capable of resynchronising the contractions of the ventricles (the heart's lower chambers) by delivering low-energy impulses to improve the pumping performance of the heart. They also provide patients with defibrillation support when abnormally fast, life-threatening heart rhythms occur.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo